Tcr vδ1 fitc

For surface marker staining of γδTc, the following anti-human antibodies from BioLegend, unless otherwise indicated, were employed: TCRγδ PE (clone B1, 1:25); TCR Vδ1 FITC (Miltenyi, clone REA173, 1:10); TCR Vδ2 PerCP (clone B6, 1:25); NKG2D APC (BD Biosciences, Mississauga, ON, Canada, 1:25); CD56 FITC (clone MEM-188, 1:5); CD69 AF700 (clone FN50, 1:4); CD94 FITC (clone DX22, 1:5); CD95 APC (clone DX2, 1:100); HLA ABC PE (clone W6/32, 1:10); FasL PE (clone NOK-1, 1:5); and CD40L APC (clone 24–31, 1:5).
Anti-human MICA/B PE (BioLegend, clone 6D4, 0.1 µg) was used to stain breast cancer cell lines.

For surface marker staining of γδ T cells, the following anti-human antibodies from BioLegend (unless otherwise indicated) were employed: TCRγδ PE (clone B1, 1:25); TCRγδ PE (Miltenyi, clone REA591, 1:10); TCRγδ BV421(clone B1, 1:10); TCR Vδ1 FITC (Miltenyi, clone REA173, 1:10); TCR Vδ2 PE (Miltenyi, clone 123R3, 1:100); TCR Vδ2 PerCP (clone B6, 1:25); CD27 AF700 (clone M-T271, 1:25); CD27 APC (clone M-T271, 1:25); CD45RA FITC (clone HI100, 1:25); CD69 AF700 (clone FN50, 1:4); CTLA-4 APC (clone L3D10, 5 μl); and PD-1 BV421 (clone EH12.2H7, 1:20).
For breast cancer cell line surface staining, anti-human MICA/B PE (clone 6D4, 0.1 μg); ULBP-2,5,6 (R&D systems, clone 165,903, 0.2 μg); ULBP-3 (R&D systems, clone 166,510, 0.04 μg); ULBP-4 (R&D systems, clone 709,116, 0.1 μg).